Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono: Cladribine reduced annualised MS relapse rate

Merck Serono: Cladribine reduced annualised MS relapse rate

23rd January 2009

Merck Serono has announced its Cladribine tablets reduced the annualised relapse rate in multiple sclerosis (MS) sufferers.

The company’s comments follow a phase III clarity trial which found a 58 per cent drop in relapse rate for patients who took small dosages of the drug and a 55 per cent cut in subjects who received high measures.

As a result, Merck Serono has said it intends to submit registration for the tablets to the European Medicines Agency (EMEA) later this year.

Elmar Schnee, executive board member at the company, commented the research marks an “important milestone” in the assessment of oral treatments for MS.

He added: “Cladribine tablets have the potential to make a real difference in the lives of patients.”

The trial involved 1,326 people who suffered from the relapsing-remitting strain of the condition.

Last month, the group said its Kuyan drug had received marketing authorisation from the European commission.

The product – for the treatment of hyperphenylalaninemia in phenylketonuria – had already been given orphan medicinal product status by the EMEA.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.